Targets › CD33
24 programs from 23 companies in 27 trials: 15 Phase 1, 9 Phase 2, 3 Phase 3; Oncology, Hematology; next expected readout Dec 2026.
Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. (UniProt, P20138)
Open in Phaseline: the race on CD33, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gruppo Italiano Malattie EMatologiche dell'Adulto | Gemtuzumab ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 3 | Acute Myeloid Leukemia | Apr 2027 |
| Princess Maxima Center for Pediatric Oncology | Gemtuzumab Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 3 | Acute Myeloid Leukemia in Children | Mar 2031 |
| University of Birmingham | Gemtuzumab ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 3 | Acute Myeloid Leukaemia | Dec 2031 |
| University of Washington | Gemtuzumab Ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 2 | Acute Myeloid Leukemia | Dec 2026 |
| National Cancer Institute (NCI) | Gemtuzumab Ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 2 | Acute Myeloid Leukemia; Core Binding Factor Acute Myeloid Leukemia | Mar 2027 |
| University of Maryland, Baltimore | Gemtuzumab ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 2 | Acute Myeloid Leukemia, Adult | Jun 2027 |
| Associazione Italiana Ematologia Oncologia Pediatrica | Gemtuzumab Ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 2 | Acute Promyelocytic Leukemia | Oct 2027 |
| M.D. Anderson Cancer Center | Gemtuzumab Ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 2 | Acute Promyelocytic Leukemia With PML-RARA; Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Dec 2027 |
| Centre Antoine Lacassagne | Gemtuzumab ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 2 | AML | Jul 2028 |
| Shaare Zedek Medical Center | Gemtuzumab Ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 2 | Leukemia, Myeloid, Acute | Sep 2028 |
| Essen Biotech | CD123/CD33 CAR-T (EB-BH2025) CAR-T cells targeting CD123 and/or CD33 sequentially | CD123, CD33 | Phase 1 | AML | Dec 2026 |
| First Affiliated Hospital of Zhejiang University | A-CAR028 Bispecific chimeric antigen receptor T-cell targeting CD33 and CLL-1 | CD33, ITGA4 | Phase 1 | Acute Myeloid Leukemia (AML) | Dec 2026 |
| Beijing GoBroad Hospital | FL-33 CAR T therapy anti-CD33 CAR-T cell therapy | CD33 | Phase 1 | Refractory/Relapsed Acute Myeloid Leukaemia | Dec 2026 |
| Masonic Cancer Center, University of Minnesota | GTB-3650 Tri-specific killer engager (TriKE) targeting CD16 on NK cells, IL-15 co-stimulation, and | CD16, IL15, CD33 | Phase 1 | Myeloid Malignancy | Mar 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | Gemtuzumab Ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 1 | Acute Myeloid Leukemia | Apr 2027 |
| Technische Universität Dresden | Gemtuzumab ozogamicin Myeloid cell surface antigen CD33 binding agent | CD33 | Phase 1 | Acute Myeloid Leukemia | Apr 2027 |
| Seattle Children's Hospital | SC-DARIC33 Anti-CD33 CAR-T cell therapy with DARIC (Dimerizing Agent Regulated Immunoreceptor Complex | CD33 | Phase 1 | Acute Myeloid Leukemia | Feb 2028 |
| University of Virginia | CD33 FPBMC anti-CD3 x anti-CD33 bispecific antibody armed fresh peripheral blood mononuclear cells | CD3E, CD33 | Phase 1 | Acute Myeloid Leukemia | Aug 2028 |
| City of Hope Medical Center | Anti-CD33 CAR T-cells anti-CD33 chimeric antigen receptor (CAR) T-cell therapy | CD33 | Phase 1 | Acute Myeloid Leukemia | Sep 2028 |
| University of Pennsylvania | CD33KO-HSPC CD33-knockout hematopoietic stem and progenitor cells to reduce CAR-T cell toxicity | CD33 | Phase 1 | Leukemia, Myeloid, Acute | Feb 2029 |
| Center for International Blood and Marrow Transplant Research | CD33CART allogeneic anti-CD33 chimeric antigen receptor-expressing T cells | CD33 | Phase 1 | Acute Myelogenous Leukemia | Dec 2029 |
| Center for International Blood and Marrow Transplant Research | CD33CART autologous anti-CD33 chimeric antigen receptor-expressing T cells | CD33 | Phase 1 | Acute Myelogenous Leukemia | Dec 2029 |
| Great Ormond Street Hospital for Children NHS Foundation Trust | BE CAR33 (Cryopreserved BE CAR33 T Cells / BE752TBTTBCAR33PBL) Base-edited CAR-T cells targeting CD33 with enhanced safety profile through base editing t | CD33 | Phase 1 | Relapsed Acute Myeloid Leukaemia | – |
| Precigen | PRGN-3006 T Cells Anti-CD33 chimeric antigen receptor (CAR) T cell therapy | CD33 | Phase 1 | Acute Myeloid Leukemia | – |
Acute Myeloid Leukemia (9) Leukemia, Myeloid, Acute (3) AML (2) Acute Myelogenous Leukemia (2) Acute Myeloid Leukemia in Children (1) Refractory/Relapsed Acute Myeloid Leukaemia (1) Acute Promyelocytic Leukemia With PML-RARA (1) Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 (1) Core Binding Factor Acute Myeloid Leukemia (1) Relapsed Acute Myeloid Leukaemia (1) Myeloid Malignancy (1) Acute Myeloid Leukaemia (1)
other (7), small molecule (5), mixed (5), antibody (4), protein or peptide (3)
Center for International Blood and Marrow Transplant Research (2) Princess Maxima Center for Pediatric Oncology (1) Beijing GoBroad Hospital (1) Shaare Zedek Medical Center (1) University of Washington (1) Seattle Children's Hospital (1) M.D. Anderson Cancer Center (1) City of Hope Medical Center (1) National Cancer Institute (NCI) (1) University of Pennsylvania (1) Great Ormond Street Hospital for Children NHS Foundation Trust (1) H. Lee Moffitt Cancer Center and Research Institute (1) Masonic Cancer Center, University of Minnesota (1) Essen Biotech (1) Gruppo Italiano Malattie EMatologiche dell'Adulto (1) University of Virginia (1) Technische Universität Dresden (1) Precigen (1) University of Birmingham (1) Associazione Italiana Ematologia Oncologia Pediatrica (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.